Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma

Annals of Oncology

Volumn 20, Issue 4, 2009, Pages 709-714

  Esmaeli, B ^a   McLaughlin, P ^a   Pro, B ^a   Samaniego, F ^a   Gayed, I ^a   Hagemeister, F ^a   Romaguera, J ^a   Cabanillas, F ^a,b   Neelapu, S S ^a   Banay, R ^a   Fayad, L ^a   Saville, M Wayne ^c   Kwak, L W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Auxilio Mutuo Cancer Center   (Puerto Rico)

^c BIOGEN   (United States)

Author keywords

Conjunctival lymphoma; Non Hodgkin's lymphoma; Ocular adnexal lymphoma; Orbital lymphoma; Radioimmuntherapy; Zevalin

Indexed keywords

IBRITUMOMAB TIUXETAN; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVA TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; EYE CANCER; EYELID CANCER; FATIGUE; FEMALE; FLUSHING; FOLLICULAR LYMPHOMA; HUMAN; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MYALGIA; NAUSEA; ORBIT CANCER; PANCYTOPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOTHERAPY; SIDE EFFECT; SKIN BRUISING;

EID: 63549103242     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn692     Document Type: Article

References (39)

1. Decaudin D, de Cremoux P, Vincent-Salomon A et al. Ocular adnexal lymphoma: A review of clinicopathologic features and treatment options. Blood 2006; 108: 1451-1460.
2. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004; 23: 6524-6534.
3. Knowles DM, Jakobiec FA, McNally L et al. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): A prospective multiparametric analysis of 108 cases during 1977 to 1987. Hum Pathol 1990; 21: 959-973.
4. Margo CE, Mulla ZD. Malignant tumors of the orbit: Analysis of the Florida Cancer Registry. Ophthalmology 1998; 105: 185-190.
5. Moslehi R, Devesa SS, Schairer C et al. Rapidly increasing incidence of ocular non-Hodgkin lymphoma. J Natl Cancer Inst 2006; 98: 936-939.
6. McKelvie PA, McNab A, Francis IC et al. Ocular adnexal lymphoproliferative disease: A series of 73 cases. Clin Exp Ophthalmol 2001; 29: 387-393.
7. Bardenstein DS. Ocular adnexal lymphoma: Classification, clinical disease, and molecular biology. Ophthalmol Clin North Am 2005; 18: 187-197.
8. Coupland SE, Krause L, Delecluse HJ et al. Lymphoproliferative lesions of the ocular adnexa: Analysis of 112 cases. Ophthalmology 1998; 105: 1430-1441.
9. Stafford SL, Kozelsky TF, Garrity JA et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol 2001; 59: 139-144.
10. Shields CL, Shields JA, Carvahlo C et al. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology 2001; 108: 979-984.
11. Fung CY, Tarbell NJ, Lucarelli MJ et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys. 2003; 57: 1382-1391.
12. Hatef E, Roberts D, McLaughlin P et al. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol 2007; 125: 1663-1667.
13. Gayed I, Eskandari MF, McLaughlin P et al. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging 2007; 110: 809-815.
14. Bolek TW, Moyses HM, Marcus RB Jr et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 1999; 44: 31-36.
15. Bhatia S, Paulino AC, Buatti JM et al. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 2002; 54: 818-823.
16. Song EK, Kim SY, Kim TM et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann Oncol 2008; 19: 242-246.
17. Ben Simon GJ, Cheung N, Mc Kelvie P et al. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology 2006; 113: 1209-1213.
18. Grillo-Lopez AJ, Dallaire BK, Mc Clure A et al. Monoclonal antibodies: A new era in the treatment of non-Hodgkin's lymphoma. Curr Pharm Biotechnol 2001; 2: 301-311.
19. Cvetkovic RS, Perry CM. Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006; 66: 791-820.
20. Plosker GL, Figgitt DP. Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803-843.
21. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
22. Winter JN. Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma. Curr Opin Hematol 2007; 14: 360-368.
23. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspective. Semin Oncol 2003; 30 (Suppl 4): 10-21.
24. Santos ES, Kharfan-Dabaja MA, Ayala E et al. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 2453-2476.
25. Chapuy B, Hohloch K, Trumper L. Yttrium 90 ibritumomab tiuxetan (Zevalin): A new bullet in the fight against malignant lymphoma? Biotechnol J 2007; 2: 1435-1443.
26. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269.
27. Esmaeli B, Murray JL, Ahmadi MA et al. Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit. Arch Ophthalmol 2002; 120: 1225-1227.
28. Cheson BD, Pfistner B, Juweid ME et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 2007; 25: 579-586.
29. Witzig TE, White CA, Gordon LE et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263-1270.
30. Emmanouilides C, Witzig TE, Gordon LI et al. Treatment with yttrium-90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 629-636.
31. Emmanouilides CE, Witzig TE, Molina A et al. Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin's lymphoma (NHL) (abstract). Proc Am Soc Clin Oncol. 2003; 22: 595 (Abstr 2392).
32. Johansson L, Carlsson J, Nilsson K. Radiosensitivity of human B-lymphocytic lymphomas in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1982; 41: 411-420.
33. Sullivan TJ, Grimes D, Bunce I. Monoclonal antibody treatment of orbital lymphoma. Ophthal Plast Reconstr Surg 2004; 20: 103-106.
34. Zinzani PL, Alinari L, Stefoni V et al. Rituximab in primary conjunctival lymphoma. Leuk Res 2005; 29: 107-108.
35. Ferreri AJ, Ponzoni M, Matinelli G et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 2005; 90: 1578-1579.
36. Rigacci L, Nassi L, Puccioni M et al. Rituximab and chlorambucil as first line treatment for low-grade ocular adnexal lymphomas. Ann Hematol 2007; 86: 565-568.
37. Parsons JT, Bova FJ, Fitzgerald CR et al. Severe dry-eye syndrome following external beam irradiation. Int J Radiat Oncol Biol Phys. 1994; 30: 775-780.
38. Durkin SR, Roos D, Higgs B et al. Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand. 2007; 85: 240-250.
39. Cogan DG, Donaldson DD, Reese AB. Clinical and pathological characteristics of radiation cataract. Arch Ophthalmol 1952; 47: 55.